Approval · Notice of Compliance 13962 · 2012
BYSTOLIC: Notice of Compliance 13962
Issued December 21, 2012
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 13962
- Date
- December 21, 2012
- Company
- Forest Laboratories Canada IncMarkham, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- New Drug Submission (NDS)
- Submission class
- New Active Substance (NAS)
- Therapeutic class
- Antihypertensive agent
Products in this notice
Medicinal ingredients
- NEBIVOLOL HCL 2.5 MG per TAB
- NEBIVOLOL HCL 5 MG per TAB
- NEBIVOLOL HCL 10 MG per TAB
- NEBIVOLOL HCL 20 MG per TAB